Shanghai Haohai Biological Technology Co., Ltd. (“Haohai Biotec”) disclosed its latest Next Day Disclosure Return and Repurchase Report, detailing the following key developments as at 7 September 2026:

Share Capital Position (post-transaction) • H-shares in issue (excluding treasury shares): 34.78 million • A-shares in issue (excluding treasury shares): 190.20 million • Total ordinary shares in issue (excluding treasury shares): 224.98 million • Treasury shares (A-shares): 3.85 million • No changes occurred in the number of issued or treasury shares on 7 September 2026; all repurchased H-shares remain pending cancellation.

Latest Repurchase on 7 September 2026 • Volume: 65,500 H-shares (0.03% of existing H-share capital) • Price range: HKD 16.57 – HKD 16.85 • Volume-weighted average price: approximately HKD 16.74 • Aggregate consideration: HKD 1.10 million • Shares will be cancelled; none retained as treasury stock.

Cumulative Buyback Activity under Current Mandate • Total H-shares repurchased since the 29 May 2026 mandate: 721,000 shares • Proportion of issued shares (ex-treasury) at mandate date: 2.07% • Estimated aggregate consideration (based on disclosed daily averages): roughly HKD 11.74 million • Remaining authority: up to 2.76 million H-shares (subject to the 3.48 million-share limit) may still be repurchased.

Repurchase Schedule & Restrictions • Mandate approval date: 29 May 2026 • Moratorium: Haohai Biotec is restricted from issuing new shares or disposing of treasury shares until 7 October 2026, pursuant to Hong Kong Listing Rule 10.06(3)(a).

Implications The company continues to utilize its share-repurchase mandate, signaling a commitment to balance-sheet optimisation. With 2.76 million H-shares still available under the current authorization and no change to total issued share capital pending cancellation, the pace and scale of future buybacks will remain headline items for tracking capital-management strategy.